The IMF at ASH 2024
  • SGL Blogs
    • Sheri Baker
    • Yelak Biru
    • Becky Bosley
    • Barbara Davis
    • Jessie Daw
    • Oya Gilbert
    • Terry Glassman
    • Linda Huguelet
    • Teresa Miceli
    • Rob Salmon
    • Jim Shoemaker
    • Michael Tuohy
    • Robin Tuohy
    • Jenn Wieworka
    • Jill Zitzewitz
  • ASH Abstracts
  • IMF Website
Select Page
Commentary on ASH 2024 Abstracts on Trispecifics for Myeloma and Treatments for High-Risk Smoldering Multiple Myeloma

Commentary on ASH 2024 Abstracts on Trispecifics for Myeloma and Treatments for High-Risk Smoldering Multiple Myeloma

Dec 7, 2024 | Sheri Baker

@szusmani shares his excitement about abstracts on tri-specifics and high-risk smoldering MM. #ASH24 #IMFASH24 #mmsm pic.twitter.com/CS6YSL3jdb

— Sheri Baker (@blondie1746) December 7, 2024

Recent Blogs

  • Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients
  • The Shape-Shifting Nature of Multiple Myeloma and the Hope in Genomic Breakthroughs
  • Learning About ‘Six-Month Resistance Training Interventions’
  • ASH Summary on Smoldering Multiple Myeloma (SMM)
  • Debate: Early Intervention for Smoldering Multiple Myeloma (SMM) — A Summary

24-hour urine test anito-cel AQUILA ASCT bispecific antibody CAR T CAR T-cell Carvykti cure dara daratumumab darzalex dexamethasone exercise fatigue frail frailty genes high-risk multiple myeloma high-risk smoldering multiple myeloma hope HOVON 143 HRMM HR SMM Iceland ide-cel infection Isatuximab iStopMM Mayo Clinic algorithm MGUS minimal residual disease MRD precursor QOL quadruplets quality of life refractory relapse RRMM Sarclisa SMM smoldering multiple myeloma stem cell transplant supportive care

SGL Blogs

  • Sheri Baker
  • Yelak Biru
  • Becky Bosley
  • Barbara Davis
  • Jessie Daw
  • Oya Gilbert
  • Linda Huguelet
  • Rob Salmon
  • Jim Shoemaker
  • Michael Tuohy
  • Robin Tuohy
  • Jenn Wieworka
  • Jill Zitzewitz
  • Teresa Miceli
  • Terry Glassman

with support from:

THIS WEBSITE IS HOSTED BY THE INTERNATIONAL MYELOMA FOUNDATION (“IMF”) FOR MULTIPLE MYELOMA SUPPORT GROUPS. THE CONTENT APPEARING ON THIS WEBPAGE IS NOT CONTROLLED OR PROVIDED BY IMF, AND IMF NEITHER WARRANTS NOR GUARANTEES THE ACCURACY OF SUCH CONTENT. THE FOREGOING NOTWITHSTANDING, THE CONTENT IS NOT A SUBSTITUTE FOR ADVICE AND SERVICE PROVIDED BY QUALIFIED AND LICENSED MEDICAL PROFESSIONALS, AND SHOULD NOT BE RELIED ON WITH RESPECT TO ANY HEALTH MATTERS. ANY HEALTH-RELATED INFORMATION FOUND HEREIN IS ONLY MADE AVAILABLE AS PART OF A GENERAL EDUCATIONAL SERVICE.